Loading
A phase 1/2 trial of adebrelimab in pancreatic cancer, run by Jiangsu HengRui Medicine Co., Ltd., not yet recruiting.
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors is a phase 1/2, randomised interventional study registered as NCT07806058 by Jiangsu HengRui Medicine Co., Ltd., with a registry enrolment figure of 140 participants, started 2026-09 and due to reach its primary completion in 2028-12-31. Interventions recorded: HRS-7172 + AG + SHR-1316; HRS-7172 + AG + SHR-1316;; HRS-7172 + AG;; HRS-7172 + AG + SHR-1316;; HRS-717 + HRS-4642+SHR-1316;; HRS-717 + HRS-4642+SHR-1316;; HRS-717 + HRS-4642;; HRS-717 + HRS-4642+SHR-1316;. Conditions listed: Pancreatic Cancer. Primary outcome: RDE in advanced pancreatic cancer with RAS mutation or amplification; Incidence and severity of adverse events (AEs) (per NCI-CTCAE V6.0 criteria); ORR assessed by the investigator. Pancreatic eligibility wording from the registry: "Locally advanced or metastatic pancreatic cancer confirmed by histology and cytology, with RAS mutation/amplification detected by tissue or blood genetic testing". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Adebrelimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Adebrelimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Adebrelimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Adebrelimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Adebrelimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Adebrelimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/